Literature DB >> 9670953

Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules.

V Apostolopoulos1, G Chelvanayagam, P X Xing, I F McKenzie.   

Abstract

Peptides bound in the groove of MHC class I molecules and detected by CTLs are not normally accessible to Ab. We now report that MUC1 peptides that are bound within the groove of MHC class I molecules (H2 and HLA) and that can be detected by CTLs can also be detected by anti-MUC1 Abs. mAbs to the middle and C-terminal regions of the class I-associated peptides but not to the N terminus were able to react with MUC1 peptides bound to H2Kb and HLA-A*0201, and only to the mid-region for H2Db, by flow cytometry and also to block CTL activity. Molecular modeling showed that the N terminus is buried (and not accessible), whereas the midpeptide residues form a loop and the C terminus is free, making these two regions accessible to Ab. The findings demonstrate for the first time that peptides associated with class I molecules can be detected by anti-peptide Abs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9670953

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Authors:  Vasso Apostolopoulos; Elizabeth Yuriev; Paul A Ramsland; Jodie Halton; Carla Osinski; Wenjun Li; Magdalena Plebanski; Hans Paulsen; Ian F C McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

3.  Thyroxine-binding antibodies inhibit T cell recognition of a pathogenic thyroglobulin epitope.

Authors:  Yang D Dai; Petros Eliades; Karen A Carayanniotis; Daniel J McCormick; Yi-Chi M Kong; Vassiliki Magafa; Paul Cordopatis; Peggy Lymberi; George Carayanniotis
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

4.  Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.

Authors:  J Gong; V Apostolopoulos; D Chen; H Chen; S Koido; S J Gendler; I F McKenzie; D Kufe
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

5.  Homology modeling and molecular dynamics simulations of MUC1-9/H-2K(b) complex suggest novel binding interactions.

Authors:  Athanassios Stavrakoudis; Ioannis G Tsoulos; Katalin Uray; Ferenc Hudecz; Vasso Apostolopoulos
Journal:  J Mol Model       Date:  2010-11-16       Impact factor: 1.810

6.  A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.

Authors:  Jianlin Gong; Yunfei Zhang; John Durfee; Desheng Weng; Chunlei Liu; Shigeo Koido; Baizheng Song; Vasso Apostolopoulos; Stuart K Calderwood
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 7.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

8.  Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells.

Authors:  Anda M Vlad; Stefan Muller; Mare Cudic; Hans Paulsen; Laszlo Otvos; Franz-Georg Hanisch; Olivera J Finn
Journal:  J Exp Med       Date:  2002-12-02       Impact factor: 14.307

9.  MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

Authors:  Vani Lakshminarayanan; Nitin T Supekar; Jie Wei; Dustin B McCurry; Amylou C Dueck; Heidi E Kosiorek; Priyanka P Trivedi; Judy M Bradley; Cathy S Madsen; Latha B Pathangey; Dominique B Hoelzinger; Margreet A Wolfert; Geert-Jan Boons; Peter A Cohen; Sandra J Gendler
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

10.  Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.

Authors:  Latha B Pathangey; Vani Lakshminarayanan; Vera J Suman; Barbara A Pockaj; Pinku Mukherjee; Sandra J Gendler
Journal:  Biomolecules       Date:  2016-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.